References
Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I. (18)F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 2012. doi:10.1007/s00259-012-2065-4.
Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468–72.
Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012;37:121–7.
Soelberg KK, Bonnema SJ, Brix T, Hegedus L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography. A systematic review. Thyroid 2012. doi:10.1089/thy.2012-0005.
Morani F, Pagano L, Prodam F, Aimaretti G, Isidoro C. Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas associates with GLUT1 plasmamembrane expression. Panminerva Med 2012;54:59–63.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bertagna, F., Giubbini, R. Comment on Rosenbaum-Krumme et al.: 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 39, 1658–1659 (2012). https://doi.org/10.1007/s00259-012-2191-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-012-2191-z